111 related articles for article (PubMed ID: 34510754)
1. Reduction-Sensitive Fluorinated-Pt(IV) Universal Transfection Nanoplatform Facilitating CT45-Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer.
Lu H; Zhang Q; He S; Liu S; Xie Z; Li X; Huang Y
Small; 2021 Oct; 17(41):e2102494. PubMed ID: 34510754
[TBL] [Abstract][Full Text] [Related]
2. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer.
Liu C; Wang N; Luo R; Li L; Yang W; Wang X; Shen M; Wu Q; Gong C
Theranostics; 2021; 11(20):9833-9846. PubMed ID: 34815789
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences.
Karlson CKS; Mohd-Noor SN; Nolte N; Tan BC
Plants (Basel); 2021 Sep; 10(10):. PubMed ID: 34685863
[TBL] [Abstract][Full Text] [Related]
4. Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo.
Liu Q; Zhao K; Wang C; Zhang Z; Zheng C; Zhao Y; Zheng Y; Liu C; An Y; Shi L; Kang C; Liu Y
Adv Sci (Weinh); 2019 Jan; 6(1):1801423. PubMed ID: 30643726
[TBL] [Abstract][Full Text] [Related]
5. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
6. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9.
He ZY; Zhang YG; Yang YH; Ma CC; Wang P; Du W; Li L; Xiang R; Song XR; Zhao X; Yao SH; Wei YQ
Hum Gene Ther; 2018 Feb; 29(2):223-233. PubMed ID: 29338433
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient activation of endogenous gene in grape using CRISPR/dCas9-based transcriptional activators.
Ren C; Li H; Liu Y; Li S; Liang Z
Hortic Res; 2022 Jan; 9():. PubMed ID: 35039855
[TBL] [Abstract][Full Text] [Related]
9. Gene transcription repression in Clostridium beijerinckii using CRISPR-dCas9.
Wang Y; Zhang ZT; Seo SO; Lynn P; Lu T; Jin YS; Blaschek HP
Biotechnol Bioeng; 2016 Dec; 113(12):2739-2743. PubMed ID: 27240718
[TBL] [Abstract][Full Text] [Related]
10. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery.
Luo N; Li J; Chen Y; Xu Y; Wei Y; Lu J; Dong R
Drug Deliv; 2021 Dec; 28(1):10-18. PubMed ID: 33336604
[TBL] [Abstract][Full Text] [Related]
11. Gene activation by a CRISPR-assisted
Xu X; Gao J; Dai W; Wang D; Wu J; Wang J
Elife; 2019 Apr; 8():. PubMed ID: 30973327
[TBL] [Abstract][Full Text] [Related]
12. RNA-guided transcriptional regulation in planta via synthetic dCas9-based transcription factors.
Piatek A; Ali Z; Baazim H; Li L; Abulfaraj A; Al-Shareef S; Aouida M; Mahfouz MM
Plant Biotechnol J; 2015 May; 13(4):578-89. PubMed ID: 25400128
[TBL] [Abstract][Full Text] [Related]
13. Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for Fuchs' Endothelial Corneal Dystrophy.
Rong Z; Gong X; Hulleman JD; Corey DR; Mootha VV
Transl Vis Sci Technol; 2020 Aug; 9(9):47. PubMed ID: 32934897
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
15. A CRISPR/dCas9 toolkit for functional analysis of maize genes.
Gentzel IN; Park CH; Bellizzi M; Xiao G; Gadhave KR; Murphree C; Yang Q; LaMantia J; Redinbaugh MG; Balint-Kurti P; Sit TL; Wang GL
Plant Methods; 2020; 16():133. PubMed ID: 33024447
[TBL] [Abstract][Full Text] [Related]
16. Targeted activation of
Luo N; Zhong W; Li J; Zhai Z; Lu J; Dong R
Nanomedicine (Lond); 2022 Aug; 17(20):1411-1427. PubMed ID: 36326013
[No Abstract] [Full Text] [Related]
17. Programmable activation of Bombyx gene expression using CRISPR/dCas9 fusion systems.
Wang XG; Ma SY; Chang JS; Shi R; Wang RL; Zhao P; Xia QY
Insect Sci; 2019 Dec; 26(6):983-990. PubMed ID: 30088341
[TBL] [Abstract][Full Text] [Related]
18. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
19. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
20. Modularized CRISPR/dCas9 effector toolkit for target-specific gene regulation.
Agne M; Blank I; Emhardt AJ; Gäbelein CG; Gawlas F; Gillich N; Gonschorek P; Juretschke TJ; Krämer SD; Louis N; Müller A; Rudorf A; Schäfer LM; Scheidmann MC; Schmunk LJ; Schwenk PM; Stammnitz MR; Warmer PM; Weber W; Fischer A; Kaufmann B; Wagner HJ; Radziwill G
ACS Synth Biol; 2014 Dec; 3(12):986-9. PubMed ID: 25524106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
